Cladribine in the treatment of hairy-cell leukaemia

Cladribine, a purine nucleoside analogue, is a safe and effective treatment for patients with hairy-cell leukaemia. It is administered at a dose of 0.09 mg/kg daily as a continuous intravenous infusion over 7 days. This chapter discusses the history, rationale, chemical structure and mechanism of ac...

Full description

Saved in:
Bibliographic Details
Published in:Best practice & research. Clinical haematology 2003-03, Vol.16 (1), p.101-116
Main Authors: Goodman, Grant R, Beutler, Ernest, Saven, Alan
Format: Article
Language:English
Subjects:
2-chlorodeoxyadenosine
Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
cladribine
Cladribine - pharmacokinetics
Cladribine - therapeutic use
Dose-Response Relationship, Drug
Follow-Up Studies
Growth Substances - administration & dosage
hairy-cell leukaemia
Humans
Interferon-alpha - administration & dosage
Leukemia, Hairy Cell - drug therapy
Leukemia, Hairy Cell - metabolism
Pentostatin - administration & dosage
purine analogue
Remission Induction
Salvage Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cladribine, a purine nucleoside analogue, is a safe and effective treatment for patients with hairy-cell leukaemia. It is administered at a dose of 0.09 mg/kg daily as a continuous intravenous infusion over 7 days. This chapter discusses the history, rationale, chemical structure and mechanism of action of cladribine. The indications for therapy and guidelines for clinical usage are reviewed. The response of hairy-cell leukaemia to cladribine, the acute and chronic complications and the risk for second malignancies are summarized. The chapter concludes with a section on salvage therapy.
ISSN:1521-6926
1532-1924
DOI:10.1016/S1521-6926(02)00089-0